Search

Introduction: COVID-19 pneumonia typically presents with high fever, cough, and shortness of breath and on thorax computed tomography (CT) peripheral ground glass opacities help the diagnosis. Although typical imaging findings for COVID-19 pneumonia are specified in thorax CT, these findings can be confused with other diseases. The aim of this study is to investigate the roles of radiological imaging and laboratory findings in the differential diagnosis of COVID-19 pneumonia and acute heart failure (AHF). Materials and Methods: In the present study, 74 patients who admitted to the emergency department with respiratory distress during the pandemic period and received a diagnosis of COVID-19 pneumonia and AHF were included. Laboratory data and radiological findings of the patients, at the time of admission, were evaluated. Result: On admission, there was no difference in age, gender between two groups. However, COVID-19 exposure history was found significantly higher in COVID-19 pneumonia patients group (p

Objective: The disease caused by Coronavirus 19 is a pandemic disease that emerged at the end of 2019 and has spread worldwide. Although it progresses as a classical upper respiratory tract infection in mild cases, it causes death by causing pneumonia and respiratory distress in severe cases. Although various drugs have been tried, there is still no specific drug treatment. The aim of this study is to investigate the demographic characteristics, risk factors, drugs used and the effects of these drugs on mortality of patients who were infected with Coronavirus 19.Materials and Methods: A total of 71 patients hospitalized in Malatya Training and Research Hospital with the diagnosis of COVID-19 due to positive test results between March 2020 and May 2020 were retrospectively rewieved and recorded from the hospital's database and the Public Health Management System. The demographic characteristics of these patients, the service they were hospitalized, the duration of hospitalization, additional diseases, survival status, and the drugs they used were recorded. statistical analyses were performed by using SPSS (IBM SPSS for Windows, ver.24) and Minitab (Statistical Software for Windows, ver.17) statistical package programs.Results: The number of male patients was statistically significantly higher than female patients (p: 0.001). Mortality rate was higher in males than females (p: 0.001). 73% of the patients had at least one additional disease. The most common additional disease was hypertension (48%). The mortality rate of patients with comorbidities was statistically significantly higher than those without (p: 0.001). In our institution 5 drug groups, including hydroxychloroquine, oseltamivir, azithromycin, favipiravir, ritonavir and lopinavir have been were routinely used against COVID-19. The most frequently used drug was hydroxychloroquine (77%). The drugs used had no effect on mortality (p: 0582).Conclusion: The results of our study indicate that the majority of those who get COVID 19 are men, age is an important risk factor, additional diseases increase the risk of mortality, and all the drugs used have no effect on mortality., Amaç: Corona Virüs 19’un neden olduğu hastalık, 2019 yılının sonunda ortaya çıkan halen Dünya genelinde yaygın olarak görülen pandemik hastalıktır. Hafif vakalarda klasik bir üst solunum enfeksiyonu şeklinde seyretse de ağır vakalarda pnömoni ve solumun sıkıntısına yol açarak ölüme neden olur. Günümüzde halan spesifik bir ilaç tedavisi bulunmamakta ve çeşitli ilaçlar tedavi için denenmektedir. Bu çalışmada, Corona Virüs 19’a yakalanan hastaların demografik özellikleri, risk faktörleri, kullanılan ilaçlar ve bu ilaçların mortalite üzerine etkilerinin araştırılması amaçlandı.Materyal ve Metot: Malatya Eğitim ve Araştırma Hastanesi’nde 2020 yılı Mart-Mayıs ayları arasında Covid 19 tanısı ile yatan ve test sonucu pozitif olan toplam 71 hasta, hastanenin veri tabanından ve Halk Sağlığı Yönetim Sisteminden retrospektif olarak taranarak kaydedildi. Bu hastaların, demografik özellikleri, yattıkları servis, yatış süreleri, ek hastalıkları, sağ kalım durumları, kullandıkları ilaçlar tespit edildi. İstatiksel analiz için SPSS (IBM SPSS for Windows, ver.24) ve Minitab (Statistical Software for Windows, ver.17) istatistik paket programları kullanılmıştır.Bulgular: Erkek hastaların sayısı kadınlara göre istatiksel anlamlı olarak yüksekti (p:0,001). Ölüm oranı erkeklerde kadınlara göre daha yüksekti (p:0,001). Hastaların 73%’de en az bir ek hastalık vardı. En fazla görülen ek hastalık hipertansiyondu (48%). Ek hastalığı olan hastaların ölüm oranı olmayanlara göre istatiksel anlamlı olarak yüksekti (p:0,001). Hastanemizde Covid 19’a karşı rutin olarak hidroksiklorokin, oseltamivir, azitromisin, favipiravir, ritonavir ve lopinavir olmak üzere beş ilaç grubu kullanılmıştı. Bu ilaçlar içerisinden en fazla kullanılan hidroksiklorokin’di (77%). Kullanılan ilaçların mortalite üzerine herhangi bir etkisi yoktu (p:0582).Sonuç: Çalışmamızın sonuçları, Covid 19 hastalığına yakalananların çoğunluğunun erkek olduğunu, yaşın önemli bir risk faktörü olduğunu, ek hastalıkların mortalite riskini artırdığını, kullanılan bütün ilaçların mortalite üzerinde herhangi bir etkisinin olmadığını göstermektedir.

Objective Older adults with co‐morbidities have been reported to be at higher risk for adverse outcomes of coronavirus disease 2019 (COVID‐19). The characteristics of COVID‐19 in older patients and its clinical outcomes in different kidney disease groups are not well known. Methods Data were retrieved from a national multicentric database supported by Turkish Society of Nephrology, which consists of retrospectively collected data between 17 April 2020 and 31 December 2020. Hospitalised patients aged 18 years or older with confirmed COVID‐19 diagnosis suffering from stage 3‐5 chronic kidney disease (CKD) or on maintenance haemodialysis (HD) treatment were included in the database. Non‐uraemic hospitalised patients with COVID‐19 were also included as the control group. Results We included 879 patients [388 (44.1%) female, median age: 63 (IQR: 50‐73) years]. The percentage of older patients in the CKD group was 68.8% (n = 188/273), in the HD group was 49.0% (n = 150/306) and in the control group was 30.4% (n = 70/300). Co‐morbidities were higher in the CKD and HD groups. The rate of presentation with severe‐critical disease was higher in the older CKD and HD groups (43.6%, 55.3% and 16.1%, respectively). Among older patients, the intensive care unit (ICU) admission rate was significantly higher in the CKD and HD groups than in the control group (38.8%, 37.3% and 15.7%, respectively). In‐hospital mortality or death and/or ICU admission rates in the older group were significantly higher in the CKD (29.3% and 39.4%) and HD groups (26.7% and 30.1%) compared with the control group (8.6% and 17.1%). In the multivariate analysis, in‐hospital mortality rates in CKD and HD groups were higher than control group [hazard ratio (HR): 4.33 (95% confidence interval [CI]: 1.53‐12.26) and HR: 3.09 (95% CI: 1.04‐9.17), respectively]. Conclusion Among older COVID‐19 patients, in‐hospital mortality is significantly higher in those with stage 3‐5 CKD and on maintenance HD than older patients without CKD regardless of demographic characteristics, co‐morbidities, clinical and laboratory data on admission.

WOS: 000393291900012 OBJECTIVE: Cinacalcet reduces parathyroid hormone levels by increasing the sensitivity of the parathyroid gland to calcium. in this study, we firstly aimed to evaluate the efficacy of cinacalcet in Turkish hemodialysis patients. MATERIAL and METHODS: 4483 hemodialysis patients were screened and 469 patients who had used cinacalcet were included in the study. the patients were divided into 4 groups according to drug usage durations (Group 1: 3 months, Group 2: 6 months, Group 3: 9 months and Group 4: 12 months). the patients' Parathormone, Ca, P and CaxP levels at the 3rd, 6th, 9th and 12th months were compared to the start of treatment and previous months. RESULTS: the levels of Parathormone, Ca, P and CaxP significantly decreased compared to their initial levels in all groups (from 1412 pg/ml to 1222 pg/mL for Parathormone, p< 0,001) in the 3rd month. However, this reduction was not continued in the subsequent months (Parathormone: 1381 pg/ml for the 12th month). CONCLUSION: Cinacalcet may not provide adequate benefit in control of hyperparathyroidism in Turkish hemodialysis patient population.